Neuroinflammation Triggers Panic Attacks via CO2

How Neuroinflammation Triggers Panic and Hyperventilation

Inhaling carbon dioxide can provoke panic attacks in susceptible individuals. A 2026 study from Brazilian universities now provides a physical explanation: specific immune cells in the brain detect rising CO₂ and initiate a fear response, leading to a hyperventilation breathing pattern disorder. This finding identifies a new biological target for treatment.

Microglia in the Brain’s Alarm Center Sense Carbon Dioxide

Researchers led by Luciane Gargaglioni at São Paulo State University focused on the locus coeruleus, a small brainstem region known as the body’s primary alarm system. This area is exquisitely sensitive to changes in blood pH caused by CO₂. The team exposed mice to air containing 20% CO₂—a potent trigger—and examined their brains six hours later. Using a stain called IBA-1, they found activated microglia in the locus coeruleus. Microglia are not passive bystanders; they are the brain’s resident immune cells that can drive neuroinflammation. Their activation signals that the brain has detected a significant homeostatic threat from the high CO₂ levels.

This activation appears to be a key step in the panic cascade. “Microglia-driven pro-inflammatory responses help detect homeostatic disturbances like CO₂ inhalation,” the authors write. Once activated, these cells likely alter the activity of neurons in the locus coeruleus, which is heavily linked to panic disorder. This provides a cellular mechanism for why people with this condition are so sensitive to CO₂ fluctuations that others tolerate. It connects a respiratory stimulus directly to a brain inflammation pathway.

A Two-Part Panic Response: Escape Behavior and Hyperventilation

The study recorded a clear two-part reaction to the CO₂ challenge in mice. The animals exhibited classic panic-like escape behaviors, including frantic jumps and running episodes. Simultaneously, they began to hyperventilate—breathing rapidly and deeply. This hyperventilation is a core component of what clinicians call a CO₂ breathing pattern disorder, where abnormal respiration lowers blood CO₂ too much, often exacerbating anxiety and physical symptoms like dizziness.

When the team tested interventions, a critical distinction emerged. They treated mice with either minocycline—a drug known to inhibit microglia—or clonazepam, a standard benzodiazepine used for panic. Both drugs reduced the escape behaviors. However, only minocycline reduced the hyperventilatory response. Clonazepam did not affect breathing patterns. This separation is vital. It suggests that while calming neuronal activity can manage the behavioral feeling of panic, addressing the underlying microglial activation may be necessary to correct the dysfunctional breathing drive itself. Neither drug changed local interleukin levels in the mouse brain, indicating minocycline’s primary action was calming microglia activity, not broadly suppressing cytokines.

Minocycline Reduces Panic and Modulates Immunity in Patients

The translational power of the finding was tested in human patients with panic disorder at the Federal University of Rio de Janeiro’s Laboratory of Panic and Respiration. Led by Antonio E. Nardi, patients underwent a CO₂ inhalation challenge, a validated experimental model for inducing panic attacks. Those treated with minocycline experienced less severe panic attacks in response to the gas compared to controls.

Furthermore, blood tests revealed minocycline produced a measurable immunomodulatory effect. It lowered levels of soluble interleukin-2 receptor alpha (IL-2sRα), a marker associated with pro-inflammatory T-cell activity, and increased levels of the anti-inflammatory cytokine IL-10. This shift toward a less inflammatory immune state aligns with the drug’s observed effect on brain microglia and suggests a systemic anti-inflammatory benefit. The study’s approach, moving from mouse neurobiology to human clinical response, provides strong evidence for the role of neuroimmune signaling in CO₂ sensitivity. The work also aligns with broader research into how breathwork and other interventions may share biological pathways with treatments that alter brain state.

New Avenues for Treating Breathing Pattern Disorders

This research moves the understanding of CO₂-induced panic and hyperventilation from a purely psychological or neurological model to a neuroimmunological one. The identification of microglia as a culprit offers a fresh therapeutic target. While repurposing minocycline requires much more clinical study and carries potential side effects, it validates the principle. Other strategies to reduce brain inflammation could be explored for managing treatment-resistant panic disorder with prominent respiratory symptoms.

For individuals and clinicians, this underscores that a disordered breathing pattern during panic may be a biologically driven symptom, not just a consequence of fear. It supports the use of breathing biofeedback to gain conscious control over an automatic response and suggests anti-inflammatory lifestyles may have neurological benefits. However, the study has limitations. The CO₂ challenge is an acute, extreme stimulus, and how closely microglial activation mirrors everyday anxiety is unclear. Long-term human trials are needed to confirm minocycline’s efficacy and safety for panic disorder.

Ultimately, the study by de Oliveira, Quagliato, and colleagues provides a compelling explanation for why the simple act of breathing can become entangled with panic. It shows that the brain senses a respiratory threat through an inflammatory lens, and quieting this immune response can calm both the mind and the breath.

Sources:
https://pubmed.ncbi.nlm.nih.gov/41633983/
https://pubmed.ncbi.nlm.nih.gov/41519251/
https://pubmed.ncbi.nlm.nih.gov/41293716/